Clinical trials: Intervention Phase
Anemia
Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients
The objective of this study is to evaluate the efficacy and safety of RBC transfusion for support of acute anemia in cardiovascular surgery patients based on the clinical outcome of renal impairment following transfusion of red…
- Trial name
- ReCePI (NCT03459287)
- Testing
- INTERCEPT, Control
- Where
- 18 sites in United States
- Volunteers
- 581 people
- Sponsor
- Cerus Corporation
Hemophilia A, Congenital
Alphanate in Immune Tolerance Induction Therapy
This is a multicenter, multinational, prospective, single-arm, nonrandomized, open-label study, planned in of approximately 25 male participants with congenital hemophilia A who will receive their first (primary) immune tolerance…
- Trial name
- NCT03095287
- Testing
- Alphanate
- Where
- 20 sites in United States, Canada and 4 more
- Volunteers
- 2 people
- Sponsor
- Grifols Therapeutics LLC
Limbal Stem Cell Deficiency
Allogeneic ABCB5-positive Limbal Stem Cells for Treatment of LSCD
The aim of this clinical trial is to investigate the efficacy (by monitoring neovascularization and epithelial defects) of up to four doses of the investigational medicinal product (IMP) LSC2 topically administered on the target…
- Trial name
- NCT03549299
- Testing
- LSC2
- Where
- 5 sites in United States, Germany
- Volunteers
- 16 people
- Sponsor
- RHEACELL GmbH & Co. KG
Osteoarthritis, Knee, Diabetic Neuropathic Pain
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-state addenda (DSA) and intervention-specific appendices (ISAs).
- Conditions
- Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
- Trial name
- CPMP (NCT05986292)
- Testing
- LY3016859 ISA, LY3556050 ISA, LY3526318 ISA
- Where
- 64 sites in United States, Puerto Rico
- Volunteers
- 10,000 people
- Sponsor
- Eli Lilly and Company
Healthy
A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 3
The purpose of this study is to characterize the delayed-type hypersensitivity (DTH) response at the site of Candin intradermal injection in the presence of a targeted immune pathway inhibitor.
- Trial name
- NCT04985955
- Testing
- Tofacitinib
- Where
- Belgium
- Volunteers
- 12 people
- Sponsor
- Janssen Research & Development, LLC
Crohn Disease
A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the efficacy of JNJ-active as measured by the change in the Crohn's Disease Activity Index (CDAI) score and Simplified Endoscopic Score for Crohn's disease (SES-CD) from baseline at Week…
- Trial name
- PRISM (NCT04102111)
- Testing
- JNJ-67864238
- Where
- 63 sites in United States, Argentina and 5 more
- Volunteers
- 48 people
- Sponsor
- Janssen Research & Development, LLC
Autistic Disorder
Field Test of Motivity.Net Software for Data Collection During Behavioral Interventions
This is a study funded by a Phase II SBIR to build and test the feasibility of a new software prototype for delivering evidence-based behavioral therapy treatment for autism.
- Trial name
- NCT03919721
- Testing
- Applied Behavioral Analysis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Experiad LLC
Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors.
- Conditions
- Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
- Trial name
- NCT07227298
- Testing
- PF-08634404, Sigvotatug Vedotin, PF-08046054/SGN-PDL1V
- Where
- 104 sites in United States, China and 7 more
- Volunteers
- 162 people
- Sponsor
- Pfizer
Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread…
- Conditions
- Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm
- Trial name
- NCT07227415
- Testing
- PF-08634404, Ipilimumab, Axitinib
- Where
- 183 sites in United States, Australia and 4 more
- Volunteers
- 224 people
- Sponsor
- Pfizer
Autism Spectrum Disorder
Virtual Reality Intervention for Skill Acquisition Support in Autism Spectrum Disorder (ASD)
A Randomized Controlled Phase II study to assess the efficacy of Floreo VR (Virtual reality) Building Social Connections as treatment for social skills in children with Autism Spectrum Disorder (ASD)
- Trial name
- NCT05791071
- Testing
- Floreo VR Building Social Connections
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Floreo, Inc.
Hemorrhoids
aCute HemORrhoidal Disease evALuation International Study
The primary objective of this study is to assess in real-life setting the effectiveness of conservative treatments on signs, symptoms and quality of life in patients consulting for hemorrhoids in acute phase of the disease
- Trial name
- CHORALIS (NCT04578730)
- Where
- France
- Volunteers
- 3,592 people
- Sponsor
- Servier Affaires Médicales
Head and Neck Squamous Cell Carcinoma
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)
This is a study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) as a first line intervention in a PD-L1 selected population with participants with recurrent or metastatic head and neck squamous cell…
- Trial name
- NCT04199104
- Testing
- Lenvatinib, Pembrolizumab
- Where
- 152 sites in United States, Australia and 17 more
- Volunteers
- 511 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer
Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)
The optimal treatment for Stage I or Stage IIA non-small cell lung cancer (NSCLC) remains controversial. Radiographic surveillance alone has been recommended for stage I and stage IIA patients after the tumor is removed…
- Trial name
- NCT01817192
- Testing
- Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay
- Where
- 49 sites in United States, France and 1 more
- Volunteers
- 420 people
- Sponsor
- Razor Genomics
Narcolepsy
An Interventional Safety Switch Study (Segue Study) of XYWAV in Narcolepsy
The rationale for the interventional, open-label, single-arm design of JZP258-401 is to evaluate the clinical experience in participants with narcolepsy transitioning treatment from Xyrem to XYWAV.
- Trial name
- NCT04794491
- Testing
- JZP-258
- Where
- 28 sites in United States
- Volunteers
- 62 people
- Sponsor
- Jazz Pharmaceuticals
Overweight and/or Obesity
A Study to Learn How Different Amounts of the Study Medicine Called PF-08656795 Are Tolerated and Act in Adults With Overweight or Obesity
This study will look at how different amounts of the study medicine, called PF-08656795, are tolerated and act in adults with overweight or obesity.
- Trial name
- NCT07876518
- Testing
- PF-08656795
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pancreatic Cancer
A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer
The purpose of this study is to determine the safety and tolerability of different doses of CP-675,206 in combination with gemcitabine and to determine the maximum dose of CP-675,206 that is well tolerated when given in…
- Trial name
- NCT00556023
- Testing
- CP-675,206 and gemcitabine
- Where
- 5 sites in Canada, Italy
- Volunteers
- 37 people
- Sponsor
- AstraZeneca
Angioplasty, Transluminal, Percutaneous Coronary
A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.
The purpose of this study is to compare the safety and effectiveness of abciximab, an anti-platelet therapy, versus placebo in patients undergoing percutaneous coronary intervention when administered in combination with two…
- Trial name
- NCT00269880
- Testing
- Heparin, Abciximab
- Volunteers
- 2,792 people
- Sponsor
- Centocor, Inc.
Critical Limb Ischemia, Peripheral Arterial Disease
Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial Dysfunction
A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of Rejuveinix in Combination With Standard Interventional Therapy for Critical Limb Ischemia Patients with Rutherford Class 4, 5 and 6 Disease
- Trial name
- RESTORE (NCT03041259)
- Testing
- Rejuveinix Low Dose, Rejuveinix High Dose
- Volunteers
- 320 people
- Sponsor
- Reven Pharmaceuticals, Inc.
Chronic Kidney Disease Stage 3
A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD)
The goal of this clinical trial is to learn about the safety (good or bad) of giving two AION-301 intravenous (IV) infusions, in adults with Stage 3 Chronic Kidney Disease (CKD).
- Trial name
- UC-MSC-CKD (NCT06721143)
- Testing
- AION-301
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- AION Healthspan, Inc.
Asthma
Clinical Trial on Education Method of Fluterol® Inhalation Inhaler for Asthma Control
A multi-center, randomized, open, non-inferiority, Phase 4 study
- Trial name
- NCT03110874
- Testing
- one-way education, two-way education
- Volunteers
- 184 people
- Sponsor
- Hanmi Pharmaceutical Company Limited